BriaCell Therapeutics Corp Asset Resilience Ratio
BriaCell Therapeutics Corp asset resilience ratio. BriaCell Therapeutics Corp (BCTXW) has an Asset Resilience Ratio of 0.00% as of January 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can BriaCell Therapeutics Corp fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of BriaCell Therapeutics Corp (2011–2025)
Asset resilience ratio of BriaCell Therapeutics Corp from 2011 to 2025. This chart shows how BriaCell Therapeutics Corp's Asset Resilience Ratio has changed over time. Read total liabilities of BriaCell Therapeutics Corp for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down BriaCell Therapeutics Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see BriaCell Therapeutics Corp balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: BriaCell Therapeutics Corp maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
BriaCell Therapeutics Corp Industry Peers by Asset Resilience Ratio
Compare BriaCell Therapeutics Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
| No industry peers found with asset resilience data. | ||
BriaCell Therapeutics Corp Asset Resilience Ratio by Year (2011–2025)
BriaCell Therapeutics Corp asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for BriaCell Therapeutics Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-07-31 | 34.05% | $7.37 Million | $21.65 Million | -10.99pp |
| 2018-07-31 | 45.04% | $1.03 Million | $2.28 Million | +8.27pp |
| 2017-07-31 | 36.78% | $601.76K | $1.64 Million | -29.92pp |
| 2015-07-31 | 66.70% | $851.24K | $1.28 Million | +66.60pp |
| 2014-07-31 | 0.10% | $2.54K | $2.59 Million | -5.26pp |
| 2013-07-31 | 5.36% | $504.49K | $9.41 Million | -0.11pp |
| 2012-07-31 | 5.48% | $564.98K | $10.32 Million | -3.48pp |
| 2011-07-31 | 8.96% | $1.11 Million | $12.35 Million | -- |
About BriaCell Therapeutics Corp
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that… Read more